Spero Therapeutics
SPRO
78 hedge funds and large institutions have $186M invested in Spero Therapeutics in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 15 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
17% more capital invested
Capital invested by funds: $159M → $186M (+$26.3M)
7.49% more ownership
Funds ownership: 57.17% → 64.67% (+7.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 80 → 78 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
65% less call options, than puts
Call options by funds: $217K | Put options by funds: $614K
Top Buyers
Top Sellers
SPRO Hedge Fund Activity: Q3 2020 in Review
78 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2020, worth a combined $186M — up 17% from $159M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SPRO and 13 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 30 added.
The largest buyer was Aquilo Capital Management, adding an estimated $30.2M. The largest seller was Renaissance Technologies, cutting an estimated $2.09M.
- 78 institutional investors held Spero Therapeutics (SPRO) as of Q3 2020, down from 80 in Q2 2020.
- Funds reported $186M of Spero Therapeutics stock for Q3 2020, up 17% quarter-over-quarter.
- 13 funds opened new Spero Therapeutics positions in Q3 2020 and 15 closed out, a net change of -2 holders.
- The largest Spero Therapeutics buyer in Q3 2020 was Aquilo Capital Management, an estimated $30.2M added.
- The largest Spero Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $2.09M sold.
Based on aggregated 13F filings for Q3 2020.